Novartis Pharmaceuticals Corporation
US FDA Approves Extavia(R) - the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease
Published in Medical Letter on the CDC and FDA, September 6th, 2009
Extavia is approved by the FDA for the treatment of relapsing forms of MS to reduce the frequency of clinical exacerbations. The therapy is also indicated for patients who have experienced a first clinical episode of MS and have features consistent with the disease as shown by magnetic resonance imaging (MRI)(4).
Keywords: Novartis Pharmaceuticals Corporation, U.S. Food and Drug Administration, FDA, Neurology, Neuroimmunology,...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
More Articles from Medical Letter on the CDC and FDA
- JAMA and Archives Journals
Study examines adverse events associated with human papillomavirus vaccine - Biopharmaceuticals
Helix BioPharma Announces the Appointment of Kazimierz Roszkowski-Sliz, M.D., Ph.D., to its Board of Directors - Mylan Inc.
Mylan Files Lawsuit Against Pittsburgh Post-Gazette - RF Surgical Systems, Inc.
St. Mary Medical Center Implements New Technology to Enhance Patient Safety in the O.R. - Malaria Vaccines
Data on malaria vaccines reported by researchers at Institute of Genetics - Anthrax
Findings in anthrax reported from G.L. Li and co-researchers - More from this issue of Medical Letter on the CDC and FDA
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
